SynthesisFrontiers in pharmacology2023

Tislelizumab plus chemotherapy versus pembrolizumab plus chemotherapy for the first-line treatment of advanced non-small cell lung cancer: systematic review and indirect comparison of randomized trials.

Yimeng Guo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.